Ivan Alfonso Velasco

Dr. Ivan Alfonso Velasco

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Imperium Académico Multidisciplinary Journal
Verified
Journal Article
Open access
PDF file
MGMartín Gomez-Lujan
Martín Gomez-Lujan
MAMelina Lucia Pineda Aguilar
Melina Lucia Pineda Aguilar
JAJosé Enrique González Araujo
José Enrique González Araujo
DLDaniela María Fernández Lugo
Daniela María Fernández Lugo
IVIvan Alfonso Velasco
Ivan Alfonso Velasco
ALAndrés Marcelo Córdova López
Andrés Marcelo Córdova López
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) worldwide, and incretin-based therapies have emerged as potential tools for organ protection beyond glucose control. This multicenter prospective study compared renal, metabolic, and cardiovascular outcomes in adults with type 2 diabetes mellitus (T2DM) treated with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) across Mexico, Colombia, and Ecuador between 2023 and 2024. A total of 512 patients (298 GLP-1 RA, 214 GIP/GLP-1 RA) were followed for 12 months. Dual GIP/GLP-1 therapy showed a significantly smaller annual eGFR decline (−0.6 vs. −1.5 mL/min/1.73 m²; p=0.001) and greater albuminuria reduction (−27.4% vs. −19.0%; p=0.02), with more participants achieving ≥30% UACR reduction (43.9% vs. 34.2%; p=0.04). Improvements in HbA1c (−1.8% vs. −1.2%), body weight (−9.1 vs. −6.4 kg), and systolic blood pressure (−8.4 vs. −6.8 mmHg) were also greater with dual therapy (all p<0.05). Inflammatory and oxidative stress markers decreased more significantly in the GIP/GLP-1 group (IL-6 −34.8%, CRP −42%, MDA −1.4 μmol/L; all p<0.02). Major renal events (CKD stage ≥4 or ≥40% eGFR decline) and cardiovascular outcomes (heart failure hospitalization, myocardial infarction, cardiovascular death) were less frequent with dual agonists, translating to a 28% relative risk reduction in composite cardiorenal events (HR 0.72; 95% CI 0.54–0.96; p=0.02). These findings demonstrate that dual GIP/GLP-1 receptor agonists provide superior renal preservation, metabolic optimization, and cardiorenal protection compared with GLP-1 RAs alone, supporting their integration into early DKD management.